TABLE 2

Susceptibility rates for ceftazidime-avibactam and comparator antimicrobial agents when tested against Gram-negative organisms isolated from patients hospitalized with pneumonia (all cases combined [PHP] and VAP; United States, 2011 to 2015)

Organism/resistant subset (no. tested [PHP/VAP])a% susceptibleb
CAZ-AVICeftazidimeMeropenemPiperacillin-tazobactamGentamicinLevofloxacin
PHPVAPPHPVAPPHPVAPPHPVAPPHPVAPPHPVAP
P. aeruginosa (3,402/415)96.697.882.485.879.178.878.279.584.890.172.578.3
    MEM-NS (710/88)86.392.054.264.80.00.042.842.064.872.731.843.2
    P/T-NS (743/85)85.690.627.238.845.340.00.00.069.480.042.852.9
    CAZ-NS (599/59)80.684.70.00.045.747.59.711.967.681.442.962.7
    MDR (613/64)82.787.531.242.222.010.919.115.648.057.816.628.1
    XDR (365/32)76.287.521.140.69.96.26.63.138.450.06.06.2
Enterobacteriaceae (6,209/604)99.999.785.086.696.897.787.688.691.194.083.487.1
    CRE (189/13)97.984.65.815.41.60.03.27.754.053.824.946.2
    MDR (674/40)98.895.026.120.071.067.537.132.544.040.024.937.5
    XDR (156/9)98.177.82.611.114.122.23.80.036.522.09.60.0
Klebsiella spp. (2,260/196)99.999.085.288.893.295.486.390.391.493.488.092.9
    ESBL (433/29)99.593.122.924.164.769.033.634.558.258.642.062.1
    MEM-NS KPN (150/8)98.775.02.70.00.00.01.30.057.362.516.737.5
Enterobacter spp. (1,304/145)99.8100.075.273.198.297.979.875.296.998.696.297.2
    CAZ-NS (324/39)99.4100.00.00.092.994.921.010.388.694.986.792.3
E. coli (1,222/126)99.9100.086.288.199.699.290.592.184.688.059.561.1
    ESBL (235/21)99.6100.028.128.697.995.274.881.066.871.418.333.3
S. marcescens (716/85)99.7100.099.797.698.298.893.396.596.697.696.196.5
P. mirabilis (319/24)100.0100.095.9100.099.7100.099.7100.084.691.766.187.5
    ESBL (39/−)100.066.797.4100.048.733.3
Citrobacter spp. (228/19)100.0100.085.184.298.7100.090.394.795.2100.094.394.7
Acinetobacter spp. (443/39)35.0c38.5c37.551.341.556.432.343.645.664.136.151.3
  • a MEM-NS, meropenem nonsusceptible (MIC, ≥4 μg/ml for P. aeruginosa and ≥2 μg/ml for Enterobacteriaceae); P/T-NS, piperacillin-tazobactam nonsusceptible (MIC, ≥16 μg/ml); CAZ-NS, ceftazidime nonsusceptible (MIC, ≥16 μg/ml for P. aeruginosa and ≥8 μg/ml for Enterobacteriaceae); ESBL, ESBL-screen-positive phenotype.

  • b U.S. FDA (CAZ-AVI [ceftazidime-avibactam]) or CLSI breakpoint criteria.

  • c Percentage inhibited at ≤8/4 μg/ml.